CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
Bakuchiol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06833996
NCT06833996N/ACompleted
CompareCT.gov

The Efficacy of Bakuchiol in Treating Post-inflammatory Hyperpigmentation

Henry Ford Health System·interventional·Posted Feb 19, 2025·Updated Feb 19, 2025

In Brief

A clinical study evaluating Bakuchiol and Vehicle for Post Inflammatory Hyperpigmentation. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Post-inflammatory hyperpigmentation (PIH) is an acquired hyper melanosis that occurs after cutaneous inflammation or injury frequently affecting darker skinned individuals. Bakuchiol is derived from plants and has inhibitory effects on melanin synthesis, which makes it a promising therapeutic intervention in the management of PIH. This study aims to evaluate the efficacy of bakuchiol in treating post inflammatory hyperpigmentation using the investigators previously validated model in comparison to acne induced PIH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost Inflammatory Hyperpigmentation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 19, 2025
Enrollment StartFeb 22, 2016
Primary CompletionMay 23, 2018
Study CompletionMay 5, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 1.4 years ago

Interventions

Bakuchioldrug

Apply bakuchiol cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days

Vehicledrug

Apply vehicle cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days